Replies to post #8322 on GTC Biotherapeutics (fka GTCB)

[go seek]

no doubt GTCB is off the radar and undervalued

anything is possible...
- a strong partnership for US ATryn would clear many doubts
and boost PPS IMO

- plus (expected) ATryn approval in the US - (w/ orphan drug status for US ATryn)... potential big driver to PPS

- results expected for DIC P2 trial 1H 2009

lot of moving parts here... and most of these are not small markets...
ATryn HD and ADs
Factors VIIa, VIII, IX and Fibrinogen
rhAAT
CD20MAb
CD137MAb

Partnerships w/
Leo Pharma
LFB
Merrimack Pharma (MM-093)
PharmaAthene (Protexia)
ProGenetics (Factor IX, Factor VIII and Fibrinogen)


With ATyrn shown to effective and approved for multiple ADs, what would GTCB's value be (?)